

NOVO NORDISK A S  
Form 6-K  
May 20, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

May 19, 2016

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

\_\_\_\_\_

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

#### **Novo Nordisk A/S – Share repurchase programme**

**Bagsværd, Denmark, 19 May 2016** – On 3 February 2016, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 3 February 2016.

Under the programme initiated 29 April 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 29 April 2016 to 3 August 2016.

Since the announcement as of 9 May 2016, the following transactions have been made under the programme:

|                                 | <b>Number of<br/>B shares</b> | <b>Average<br/>purchase price</b> | <b>Transaction<br/>value, DKK</b> |
|---------------------------------|-------------------------------|-----------------------------------|-----------------------------------|
| Accumulated, last announcement  | 619,000                       |                                   | 221,753,958                       |
| 9 May 2016                      | 138,000                       | 357.49                            | 49,333,068                        |
| 10 May 2016                     | 150,000                       | 360.38                            | 54,057,660                        |
| 11 May 2016                     | 155,000                       | 358.36                            | 55,546,219                        |
| 12 May 2016                     | 150,000                       | 356.59                            | 53,489,055                        |
| 13 May 2016                     | 145,000                       | 353.93                            | 51,319,241                        |
| 17 May 2016                     | 155,000                       | 359.90                            | 55,785,244                        |
| 18 May 2016                     | 130,000                       | 358.14                            | 46,558,447                        |
| Accumulated under the programme | 1,642,000                     |                                   | 587,842,892                       |

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 227,000 B shares in the period from 9 May 2016 to 18 May 2016. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 13,719,645 B shares of DKK 0.20, corresponding to 0.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 3 February 2016. As of 18 May 2016, Novo Nordisk has repurchased a total of 11,788,000 B shares equal to a transaction value of DKK 4,217,397,617.

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube*

## **Further information**

### *Media:*

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com  
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com

### *Investors:*

Peter Hugrefte Ankersen +45 3075 9085 phak@novonordisk.com  
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com  
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

|                         |               |               |                     |
|-------------------------|---------------|---------------|---------------------|
|                         |               | Telephone:    | Internet:           |
| <b>Novo Nordisk A/S</b> | Novo Allé     |               | www.novonordisk.com |
| Investor Relations      | 2880 Bagsværd | +45 4444 8888 | CVR no:             |
|                         | Denmark       |               | 24 25 67 90         |

Company announcement No 40 / 2016

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: May 19, 2016

Lars Rebien Sørensen,

Chief Executive Officer